Victoria Alvarez

List of Publications by Year
in descending order

231	21,081	36271 51	12933 131
papers	citations	h-index	g-index

241	241	241	24737
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The FCGR2A rs1801274 polymorphism was associated with the risk of death among COVID-19 patients. Clinical Immunology, 2022, 236, 108954.	1.4	7
2	FURIN gene variants (rs6224/rs4702) as potential markers of death and cardiovascular traits in severe COVIDâ€19. Journal of Medical Virology, 2022, 94, 3589-3595.	2.5	4
3	Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 79-83.	1.1	2
4	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
5	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
6	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	1.5	8
7	The Interferon-induced transmembrane protein 3 gene (IFITM3) rs12252 C variant is associated with COVID-19. Cytokine, 2021, 137, 155354.	1.4	58
8	Long runs of homozygosity are associated with Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 142.	2.4	6
9	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	2.8	29
10	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
11	A series of cases with Huntington-like phenotype and intermediate repeats in HTT. Journal of the Neurological Sciences, 2021, 425, 117452.	0.3	3
12	TheTNF-Î±(â€“238 G/A) polymorphism could protect against development of severe sepsis. Innate Immunity, 2021, 27, 409-420.	1.1	7
13	Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity. International Immunopharmacology, 2021, 98, 107825.	1.7	18
14	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. Brain, 2021, 144, 2798-2811.	3.7	7
15	Cancer in Parkinsonâ€™s Disease: An Approximation to the Main Risk Factors. Neurodegenerative Diseases, 2021, 21, 36-41.	0.8	1
16	Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study. Journal of Personalized Medicine, 2021, 11, 1318.	1.1	7
17	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	5.8	44
18	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	1.5	35

#	Article	IF	Citations
19	Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene, 2020, 762, 145102.	1.0	154
20	Capillary electrophoresis of PCR fragments with 5Â´-labelled primers for testing the SARS-Cov-2. Journal of Virological Methods, 2020, 284, 113937.	1.0	7
21	Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders. Brain, 2020, 143, 2771-2787.	3.7	50
22	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.5	7
23	Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information. Nature Communications, 2020, 11, 1041.	5.8	22
24	Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism. Movement Disorders, 2019, 34, 1547-1561.	2.2	44
25	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	4.9	1,414
26	The N125S polymorphism in the cathepsin G gene (rs45567233) is associated with susceptibility to osteomyelitis in a Spanish population. PLoS ONE, 2019, 14, e0220022.	1.1	8
27	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	2.2	47
28	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.4	111
29	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	2.2	66
30	Mitochondria function associated genes contribute to Parkinsonâ€™s Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	2.5	95
31	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	2.8	26
32	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinsonâ€™s disease heritability. Npj Parkinson's Disease, 2019, 5, 6.	2.5	83
33	The Epistasis Project: A Multi-Cohort Study of the Effects of BDNF, DBH, and SORT1 Epistasis on Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2019, 68, 1535-1547.	1.2	11
34	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
35	Reply to: â€œMitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletionâ€• Movement Disorders, 2019, 34, 1932-1933.	2.2	0
36	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	1.5	21

#	Article	IF	Citations
37	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	4.9	15
38	Genetically elevated highâ€density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 595-598.	1.2	2
39	Screening of the Filamin C Gene in a Large Cohort of Hypertrophic Cardiomyopathy Patients. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	68
40	The p. R151C Polymorphism in MC1R Gene Modifies the Age of Onset in Spanish Huntingtonâ€™s Disease Patients. Molecular Neurobiology, 2017, 54, 3906-3910.	1.9	5
41	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
42	Poor phenotype-genotype association in a large series of patients with Type III Bartter syndrome. PLoS ONE, 2017, 12, e0173581.	1.1	27
43	KCNQ1 gene variants in the risk for type 2 diabetes and impaired renal function in the Spanish Renastur cohort. Molecular and Cellular Endocrinology, 2016, 427, 86-91.	1.6	19
44	Circulating microRNAs in Huntingtonâ€™s disease: Emerging mediators in metabolic impairment. Pharmacological Research, 2016, 108, 102-110.	3.1	72
45	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	2.8	56
46	Assessing the role of TUBA4A gene in frontotemporal degeneration. Neurobiology of Aging, 2016, 38, 215.e13-215.e14.	1.5	9
47	Analysis of theCHCHD10gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	3.7	56
48	A labor and cost effective next generation sequencing of PKHD1 in autosomal recessive polycystic kidney disease patients. Gene, 2015, 561, 165-169.	1.0	7
49	The screening of the 3â€²UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinsonâ€™s disease. Journal of Human Genetics, 2014, 59, 346-348.	1.1	14
50	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	1.5	92
51	Non Optical Semi-Conductor Next Generation Sequencing of the Main Cardiac QT-Interval Duration Genes in Pooled DNA Samples. Journal of Cardiovascular Translational Research, 2014, 7, 133-137.	1.1	17
52	A labor- and cost-effective non-optical semiconductor (Ion Torrent) next-generation sequencing of the SLC12A3 and CLCNKA/B genes in Gitelmanâ€™s syndrome patients. Journal of Human Genetics, 2014, 59, 376-380.	1.1	15
53	Mutations in filamin C cause a new form of familial hypertrophic cardiomyopathy. Nature Communications, 2014, 5, 5326.	5.8	154
54	MiRNA Profile in the Substantia Nigra of Parkinsonâ€™s Disease and Healthy Subjects. Journal of Molecular Neuroscience, 2014, 54, 830-836.	1.1	58

#	Article	IF	Citations
55	Endothelial (NOS3 E298D) and inducible (NOS2 exon 22) nitric oxide synthase polymorphisms, as well as plasma NOx, influence sepsis development. Nitric Oxide - Biology and Chemistry, 2014, 42, 79-86.	1.2	10
56	Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neuroscience Letters, 2014, 562, 45-49.	1.0	30
57	The sex-specific associations of the aromatase gene with Alzheimerâ€™s disease and its interaction with IL10 in the Epistasis Project. European Journal of Human Genetics, 2014, 22, 216-220.	1.4	35
58	Mutation Analysis of the Main Hypertrophic Cardiomyopathy Genes Using Multiplex Amplification and Semiconductor Next-Generation Sequencing. Circulation Journal, 2014, 78, 2963-2971.	0.7	51
59	Role of plasma matrix-metalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients. Scientific Reports, 2014, 4, 5002.	1.6	46
60	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
61	Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1309.e1-1309.e7.	1.5	29
62	Profile of microRNAs in the plasma of Parkinsonâ€™s disease patients and healthy controls. Journal of Neurology, 2013, 260, 1420-1422.	1.8	132
63	Mutational Screening of PARKIN Identified a 3â€² UTR Variant (rs62637702) Associated with Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2013, 50, 264-269.	1.1	11
64	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
65	The G263X MYBPC3 mutation is a common and low-penetrant mutation for hypertrophic cardiomyopathy in the region of Asturias (Northern Spain). International Journal of Cardiology, 2013, 168, 4555-4556.	0.8	9
66	Profile of microRNAs in the plasma of hypertrophic cardiomyopathy patients compared to healthy controls. International Journal of Cardiology, 2013, 167, 3075-3076.	0.8	9
67	Association between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohort. Gene, 2013, 520, 73-76.	1.0	21
68	SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. Clinical Genetics, 2013, 83, 257-262.	1.0	94
69	Do Not Trust the Pedigree: Reduced and Sex-Dependent Penetrance at a Novel Mutation Hotspot inATL1Blurs Autosomal Dominant Inheritance of Spastic Paraplegia. Human Mutation, 2013, 34, 860-863.	1.1	20
70	No differential DNA methylation of PARK2 in brain of Parkinson's disease patients and healthy controls. Movement Disorders, 2013, 28, 2032-2033.	2.2	14
71	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Molecular Psychiatry, 2013, 18, 461-470.	4.1	103
72	Novel <scp>Lrrk2</scp>â€p.<scp>S1761R</scp> mutation is not a common cause of Parkinson's disease in Spain. Movement Disorders, 2013, 28, 248-248.	2.2	1

#	Article	IF	Citations
73	A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients. Pharmacogenetics and Genomics, 2013, 23, 445-448.	0.7	35
74	A CommonAPOEPolymorphism Is an Independent Risk Factor for Reduced Glomerular Filtration Rate in the Spanish RENASTUR Cohort. CardioRenal Medicine, 2013, 3, 113-119.	0.7	9
75	Genetics of Type III Bartter Syndrome in Spain, Proposed Diagnostic Algorithm. PLoS ONE, 2013, 8, e74673.	1.1	16
76	A spastic paraplegia mouse model reveals REEP1-dependent ER shaping. Journal of Clinical Investigation, 2013, 123, 4273-4282.	3.9	74
77	Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. Movement Disorders, 2012, 27, 1823-1826.	2.2	14
78	Resequencing the Whole MYH7 Gene (Including the Intronic, Promoter, and 3â€² UTR Sequences) in Hypertrophic Cardiomyopathy. Journal of Molecular Diagnostics, 2012, 14, 518-524.	1.2	20
79	Common European Mitochondrial Haplogroups in the Risk for Psoriasis and Psoriatic Arthritis. Genetic Testing and Molecular Biomarkers, 2012, 16, 621-623.	0.3	11
80	Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. Neurobiology of Aging, 2012, 33, 202.e1-202.e13.	1.5	51
81	Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. Molecular Genetics and Metabolism, 2012, 105, 525-527.	0.5	27
82	Resequencing of the IL12B gene in psoriasis patients with the rs6887695/rs3212227 risk genotypes. Cytokine, 2012, 60, 27-29.	1.4	15
83	Effect of CYP3A5, CYP3A4, and ABCB1 Genotypes as Determinants of Tacrolimus Dose and Clinical Outcomes After Heart Transplantation. Transplantation Proceedings, 2012, 44, 2635-2638.	0.3	26
84	A Search for SNCA 3â€² UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2012, 47, 425-430.	1.1	49
85	Interaction of insulin and PPAR-Î± genes in Alzheimerâ€™s disease: the Epistasis Project. Journal of Neural Transmission, 2012, 119, 473-479.	1.4	20
86	Mitochondrial DNA polymorphisms/haplogroups in hereditary spastic paraplegia. Journal of Neurology, 2012, 259, 246-250.	1.8	9
87	Interactions between PPAR-Î± and inflammation-related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis Project. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 39-47.	0.4	13
88	Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clinical Chemistry and Laboratory Medicine, 2011, 49, 825-833.	1.4	49
89	Lrrk2 p.Q1111H substitution and Parkinsonâ€™s disease in Latin America. Parkinsonism and Related Disorders, 2011, 17, 629-631.	1.1	15
90	Role of serotonergic-related systems in suicidal behavior: Data from a caseâ€“control association study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1518-1524.	2.5	21

#	Article	IF	Citations
91	Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiology of Aging, 2011, 32, 756.e11-756.e15.	1.5	82
92	KCNQ1 gene variants and risk of newâ€onset diabetes in tacrolimusâ€treated renalâ€transplanted patients. Clinical Transplantation, 2011, 25, E284-91.	0.8	29
93	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708
94	Using mitochondrial DNA to test the hypothesis of a European post-glacial human recolonization from the Franco-Cantabrian refuge. Heredity, 2011, 106, 37-45.	1.2	40
95	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry, 2011, 16, 903-907.	4.1	529
96	Lack of association between protocadherin 11-X/Y (PCDH11X and PCDH11Y) polymorphisms and late onset Alzheimer's disease. Brain Research, 2011, 1383, 252-256.	1.1	16
97	Influence of endothelial nitric oxide synthase polymorphisms in psoriasis risk. Archives of Dermatological Research, 2011, 303, 445-449.	1.1	16
98	Late-onset Alzheimer's disease is associated with mitochondrial DNA 7028C/haplogroup H and D310 poly-C tract heteroplasmy. Neurogenetics, 2011, 12, 345-346.	0.7	33
99	Amyloid Precursor Protein Gene (APP) Variation in Late-Onset Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2011, 45, 5-9.	1.1	4
100	Replication of MAPT and SNCA, but not PARK16â€18, as susceptibility genes for Parkinson's disease. Movement Disorders, 2011, 26, 819-823.	2.2	64
101	Mitochondrial DNA and TFAM gene variation in early-onset myocardial infarction: Evidence for an association to haplogroup H. Mitochondrion, 2011, 11, 176-181.	1.6	29
102	Gitelman syndrome in Gypsy paediatric patients carrying the same intron 9 + 1 G>T mutation. Clinical features and impact on quality of life. Nephrology Dialysis Transplantation, 2011, 26, 151-155.	0.4	15
103	Profile of MicroRNAs Differentially Produced in Hearts from Patients with Hypertrophic Cardiomyopathy and Sarcomeric Mutations. Clinical Chemistry, 2011, 57, 1614-1616.	1.5	28
104	Pharmacogenetics of tacrolimus: ready for clinical translation?. Kidney International Supplements, 2011, 1, 58-62.	4.6	13
105	New Psoriasis Susceptibility Genes: Momentum for Skin-Barrier Disruption. Journal of Investigative Dermatology, 2011, 131, 1003-1005.	0.3	20
106	A functional polymorphism in MMP1 could influence osteomyelitis development. Journal of Bone and Mineral Research, 2010, 25, 912-919.	3.1	28
107	Interactions between functional serotonergic polymorphisms and demographic factors influence personality traits in healthy Spanish Caucasians. Psychiatric Genetics, 2010, 20, 171-178.	0.6	19
108	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. Journal of Alzheimer's Disease, 2010, 22, 247-255.	1.2	54

#	Article	IF	Citations
109	Apolipoprotein Îµ4 allele is associated with psoriasis severity. Archives of Dermatological Research, 2010, 302, 145-149.	1.1	18
110	Apolipoprotein Îµ4 allele is associated with Psoriasis severity: reply. Archives of Dermatological Research, 2010, 302, 237-238.	1.1	8
111	Mutational spectrum of the SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with hereditary spastic paraplegia. BMC Neurology, 2010, 10, 89.	0.8	49
112	Analysis of the Microâ€RNAâ€133 and PITX3 genes in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1234-1239.	1.1	33
113	Hyperintensity in the basis pontis: Atypical neuroradiological findings in a woman with FXTAS. Movement Disorders, 2010, 25, 649-650.	2.2	8
114	The dopamine Î²-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Medical Genetics, 2010, 11, 162.	2.1	50
115	Mutation analysis of the LCE3B/LCE3C genes in Psoriasis. BMC Medical Genetics, 2010, 11, 45.	2.1	24
116	Functional polymorphisms in genes of the Angiotensin and Serotonin systems and risk of hypertrophic cardiomyopathy: AT1R as a potential modifier. Journal of Translational Medicine, 2010, 8, 64.	1.8	21
117	FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients. Neuroscience Letters, 2010, 479, 22-25.	1.0	46
118	Genetic variation at the CCR5/CCR2 gene cluster and risk of psoriasis and psoriatic arthritis. Cytokine, 2010, 50, 114-116.	1.4	22
119	Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochemical and Biophysical Research Communications, 2010, 397, 576-579.	1.0	14
120	Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 26-31.	2.5	37
121	Espectro mutacional del gen SCN5A en pacientes espaÃ±oles con sÃndrome de Brugada. Revista Espanola De Cardiologia, 2010, 63, 856-859.	0.6	9
122	Lack of Association between Endothelin-1 Gene Variants and Myocardial Infarction. Journal of Atherosclerosis and Thrombosis, 2009, 16, 388-395.	0.9	14
123	Clinical and Analytical Findings in Gitelmanâ€™s Syndrome Associated with Homozygosity for the c.1925 G>A SLC12A3 Mutation. American Journal of Nephrology, 2009, 30, 218-221.	1.4	7
124	5â€²-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiology of Disease, 2009, 33, 164-170.	2.1	24
125	Mutation analysis of the myocyte enhancer factor 2A gene (MEF2A) in patients with left ventricular hypertrophy/hypertrophic cardiomyopathy. American Journal of Medical Genetics, Part A, 2009, 149A, 286-289.	0.7	5
126	Lrrk2 R1441G-related Parkinsonâ€™s disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics, 2009, 10, 347-353.	0.7	41

#	Article	IF	Citations
127	Mutational screening of the mortalin gene (HSPA9) in Parkinsonâ€™s disease. Journal of Neural Transmission, 2009, 116, 1289-1293.	1.4	74
128	Lack of association between angiotensin Iâ€converting enzyme insertion/deletion polymorphism and psoriasis or psoriatic arthritis in Spain. International Journal of Dermatology, 2009, 48, 1320-1323.	0.5	14
129	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	9.4	2,155
130	Polymorphisms of the ILâ€1 Gene Complex Are Associated With Alcohol Dependence in Spanish Caucasians: Data From an Association Study. Alcoholism: Clinical and Experimental Research, 2009, 33, 2147-2153.	1.4	19
131	Mutational screening of the Mitochondrial transcription factors B1 and B2 (TFB1M and TFB2M) in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 468-470.	1.1	4
132	Differential role of serotonergic polymorphisms in alcohol and heroin dependence. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 695-700.	2.5	35
133	Mutations in Sarcomeric Genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in Patients With Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2009, 62, 48-56.	0.4	19
134	ImplicaciÃ³n de polimorfismos serotoninÃ©rgicos en la gravedad clÃnica del trastorno de pÃ¡nico. Revista De PsiquiatrÃa Y Salud Mental, 2009, 2, 35-41.	1.0	5
135	Role of serotonergic polymorphisms in the clinical severity of the panic disorder. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2009, 2, 35-41.	0.2	1
136	Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. Journal of Neuroinflammation, 2009, 6, 22.	3.1	46
137	Espectro mutacional de los genes sarcomÃ©ricos MYH7, MYBPC3, TNNT2, TNNI3 y TPM1 en pacientes con miocardiopatÃa hipertrÃ³fica. Revista Espanola De Cardiologia, 2009, 62, 48-56.	0.6	51
138	A search for cyclophilinâ€A gene variants in cyclosporine Aâ€treated renal transplanted patients. Clinical Transplantation, 2008, 22, 722-729.	0.8	17
139	A search for cyclophilinâ€A gene (PPIA) variation and its contribution to the risk of atherosclerosis and myocardial infarction. International Journal of Immunogenetics, 2008, 35, 159-164.	0.8	13
140	Mitochondrial transcription factor A (TFAM) gene variation in Parkinson's disease. Neuroscience Letters, 2008, 432, 79-82.	1.0	30
141	Association study between obsessiveâ€“compulsive disorder and serotonergic candidate genes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 765-770.	2.5	47
142	Association between Heroin Dependence and 5-HT_{2A} Receptor Gene Polymorphisms. European Addiction Research, 2008, 14, 47-52.	1.3	20
143	Association Between the Stin2 VNTR Polymorphism of the Serotonin Transporter Gene and Treatment Outcome in Alcohol-Dependent Patients. Alcohol and Alcoholism, 2008, 43, 516-522.	0.9	26
144	IL-1Î² (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. Genetics in Medicine, 2008, 10, 215-223.	1.1	50

#	Article	IF	Citations
145	Mitochondrial Transcription Factor A (TFAM) Gene Variation and Risk of Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 13, 275-280.	1.2	25
146	The Sp1/Egr1-tandem Repeat Polymorphism in the 5-Lipoxygenase Gene Promoter is not Associated With Late Onset Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2008, 22, 177-180.	0.6	10
147	Association study of the interleukin-1 gene complex and tumor necrosis factor alpha gene with suicide attempts. Psychiatric Genetics, 2008, 18, 147-150.	0.6	11
148	Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts. Psychiatric Genetics, 2008, 18, 213-218.	0.6	29
149	Mitochondrial Transcription Factors TFA, TFB1 and TFB2: A Search for DNA Variants/Haplotypes and the Risk of Cardiac Hypertrophy. Disease Markers, 2008, 25, 131-139.	0.6	10
150	Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 Genes in the Risk of Atherosclerosis and Myocardial Infarction. Cell Cycle, 2007, 6, 620-625.	1.3	40
151	Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 741-745.	2.5	38
152	The NOS3 (27-bp repeat, intron 4) polymorphism is associated with susceptibility to osteomyelitis. Nitric Oxide - Biology and Chemistry, 2007, 16, 44-53.	1.2	28
153	Mitochondrial haplogroup T is negatively associated with the status of elite endurance athlete. Mitochondrion, 2007, 7, 354-357.	1.6	52
154	Myocyte enhancing factor-2A in Alzheimer's disease: Genetic analysis and association with MEF2A-polymorphisms. Neuroscience Letters, 2007, 411, 47-51.	1.0	16
155	No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes. Neuroscience Letters, 2007, 413, 202-205.	1.0	25
156	Prevalence and spectrum of mutations in the sarcomeric troponin T and I genes in a cohort of Spanish cardiac hypertrophy patients. International Journal of Cardiology, 2007, 121, 115-116.	0.8	8
157	Vesicoureteric reflux and tumor necrosis factor-Î± gene polymorphism. Journal of Pediatric Urology, 2007, 3, 24-27.	0.6	4
158	Lack of association between endothelial nitric oxide synthase (NOS3) gene polymorphisms and suicide attempts. Behavioral and Brain Functions, 2007, 3, 32.	1.4	6
159	Screening of the endothelin1 gene (EDN1) in a cohort of patients with essential left ventricular hypertrophy.. Annals of Human Genetics, 2007, 71, 601-610.	0.3	20
160	Distal RTA with nerve deafness: clinical spectrum and mutational analysis in five children. Pediatric Nephrology, 2007, 22, 825-828.	0.9	37
161	Negative evidences in association between apolipoprotein E polymorphism and panic disorder. European Psychiatry, 2006, 21, 59-61.	0.1	5
162	N-acetyltransferase-2 polymorphisms and schizophrenia. European Psychiatry, 2006, 21, 333-337.	0.1	5

#	Article	IF	Citations
163	Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2. Neuroscience Letters, 2006, 410, 80-84.	1.0	52
164	Mitochondrial DNA haplogroups in Spanish patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2006, 112, 202-206.	0.8	57
165	LRRK2 mutations are a common cause of Parkinson's disease in Spain. European Journal of Neurology, 2006, 13, 391-394.	1.7	60
166	A new de novo Notch3 mutation causing CADASIL. European Journal of Neurology, 2006, 13, 628-631.	1.7	45
167	The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clinical and Experimental Immunology, 2006, 143, 404-413.	1.1	80
168	Interleukin-1 Gene Complex in Schizophrenia: An Association Study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 678-680.	1.1	12
169	Recessive hyperekplexia due to a new mutation (R100H) in the GLRA1 gene. Movement Disorders, 2005, 20, 1626-1629.	2.2	16
170	The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. Journal of Medical Genetics, 2005, 43, 167-169.	1.5	52
171	Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism. Neuroscience Letters, 2005, 380, 257-259.	1.0	7
172	LRRK2 R1441G in Spanish patients with Parkinson's disease. Neuroscience Letters, 2005, 382, 309-311.	1.0	97
173	Hypertrophic cardiomyopathy linked to homozygosity for a new mutation in the myosin-binding protein C gene (A627V) suggests a dosage effect. International Journal of Cardiology, 2005, 102, 501-507.	0.8	24
174	Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. Journal of the Neurological Sciences, 2005, 236, 49-54.	0.3	97
175	In Vivo Interleukin-6 Protects Neutrophils from Apoptosis in Osteomyelitis. Infection and Immunity, 2004, 72, 3823-3828.	1.0	83
176	A new mutation (intron 9 +1 G>T) in the SLC12A3 gene is linked to Gitelman syndrome in Gypsies. Kidney International, 2004, 65, 25-29.	2.6	59
177	A single-nucleotide polymorphism in the human p27kip1 gene (-838C>A) affects basal promoter activity and the risk of myocardial infarction. BMC Biology, 2004, 2, 5.	1.7	21
178	Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neuroscience Letters, 2004, 370, 151-154.	1.0	65
179	Renin-angiotensin system polymorphisms and renal scarring. Pediatric Nephrology, 2003, 18, 110-114.	0.9	30
180	IL-1Î± (â^'â€‰889) promoter polymorphism is a risk factor for osteomyelitis. , 2003, 119A, 132-136.		35

#	Article	IF	Citations
181	Association between genetic variation in the Y chromosome and hypertension in myocardial infarction patients. , 2003, 122A, 234-237.		17
182	Influence of anticalcineurinic therapy in plasma homocysteine levels of renal transplant recipients: a prospective study. Transplantation Proceedings, 2003, 35, 1739-1741.	0.3	7
183	Hypertrophic Cardiomyopathy: Low Frequency of Mutations in the Î²-Myosin Heavy Chain (MYH7) and Cardiac Troponin T (TNNT2) Genes among Spanish Patients. Clinical Chemistry, 2003, 49, 1279-1285.	1.5	62
184	5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clinical Science, 2003, 104, 241-245.	1.8	28
185	5-Hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clinical Science, 2003, 104, 241.	1.8	50
186	Apolipoprotein E genotype and schizophrenia: further negative evidence. Acta Psychiatrica Scandinavica, 2002, 105, 71-75.	2.2	14
187	Variation in the lipoprotein receptor-related protein, Î±2-macroglobulin and lipoprotein receptor-associatedprotein genes in relation to plasma lipid levels and riskof early myocardial infarction. Coronary Artery Disease, 2002, 13, 251-254.	0.3	24
188	Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. Neuroscience Letters, 2002, 329, 149-152.	1.0	23
189	Association between the TNFÎ±-308 A/G polymorphism and the onset-age of Alzheimer disease. American Journal of Medical Genetics Part A, 2002, 114, 574-577.	2.4	69
190	Effects of antiretroviral therapy in patients with Charcot-Marie-Tooth disease type 1A. Journal of Neurology, 2002, 249, 940-941.	1.8	7
191	Association between the NOS3 (â^'786 T/C) and the ACE (I/D) DNA Genotypes and Early Coronary Artery Disease. Nitric Oxide - Biology and Chemistry, 2001, 5, 343-348.	1.2	81
192	Early-onset Parkinsonâ€™s disease associated with a new parkin mutation in a Spanish family. Neuroscience Letters, 2001, 313, 108-110.	1.0	17
193	Lack of association between polymorphisms of the coagulation factor VII and myocardial infarction in middle-aged Spanish men. International Journal of Cardiology, 2001, 80, 209-212.	0.8	20
194	Variation at the Angiotensin-Converting Enzyme and Endothelial Nitric Oxide Synthase Genes Is Associated With the Risk of Esophageal Varices Among Patients With Alcoholic Cirrhosis. Journal of Cardiovascular Pharmacology, 2001, 38, 833-839.	0.8	13
195	Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. American Journal of Medical Genetics Part A, 2001, 105, 76-78.	2.4	48
196	Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes and Immunity, 2001, 2, 191-195.	2.2	150
197	De novo partial duplication of 17p associated with Charcot-Marie-Tooth disease type 1A. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 703-704.	0.9	5
198	Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. Blood Coagulation and Fibrinolysis, 2000, 11, 485-490.	0.5	24

#	Article	IF	Citations
199	CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes and Immunity, 2000, 1, 288-289.	2.2	120
200	Analysis of chromosome 6p in Spanish families with recessive polycystic kidney disease. Pediatric Nephrology, 2000, 14, 205-207.	0.9	11
201	Genetic variation in the renin-angiotensin system and athletic performance. European Journal of Applied Physiology, 2000, 82, 117-120.	1.2	168
202	Synergistic Effect between Apolipoprotein E and Angiotensinogen Gene Polymorphisms in the Risk for Early Myocardial Infarction. Clinical Chemistry, 2000, 46, 1910-1915.	1.5	65
203	A High Factor II/Factor X Functional Ratio Is Not a Useful Predictor of the FII G20210A Gene Mutation in Thromboembolic Patients Undergoing Oral Anticoagulant Treatment. Clinical Chemistry, 2000, 46, 886-887.	1.5	0
204	Two Expressive Polymorphisms on the Endothelial Nitric Oxide Synthase Gene (intron4, 27 bp repeat) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.8	18
205	Normal Frequencies of the C677T Genotypes on the Methylenetetrahydrofolate Reductase (MTHFR) Gene Among Lymphoproliferative Disorders but not in Multiple Myeloma. Leukemia and Lymphoma, 2000, 39, 607-612.	0.6	25
206	Angiotensin converting enzyme and endothelial nitric oxide synthase DNA polymorphisms and late onset Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 733-736.	0.9	83
207	Multiple endocrine neoplasia type 1 (MEN1): clinical heterogeneity in a large family with a nonsense mutation in the MEN1 gene (Trp471Stop). Clinical Endocrinology, 1999, 50, 309-313.	1.2	12
208	N-Acetyltransferase-2, Glutathione S-Transferase M1, Alcohol Dehydrogenase, and Cytochrome P450IIE1 Genotypes in Alcoholic Liver Cirrhosis: A Case?Control Study. Scandinavian Journal of Gastroenterology, 1999, 34, 303-307.	0.6	36
209	Association between an Î±2 Macroglobulin DNA Polymorphism and Late-Onset Alzheimer's Disease. Biochemical and Biophysical Research Communications, 1999, 264, 48-50.	1.0	48
210	The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation. Blood Coagulation and Fibrinolysis, 1999, 10, 303.	0.5	39
211	The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coagulation and Fibrinolysis, 1999, 10, 39.	0.5	23
212	Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. Human Genetics, 1998, 102, 483-486.	1.8	42
213	Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovascular Research, 1998, 40, 375-379.	1.8	104
214	Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck. Journal of Clinical Pathology, 1998, 51, 520-524.	1.0	31
215	Genetic polymorphism of N-acetyltransferase-2, glutathione S- transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. Journal of Clinical Pathology, 1998, 51, 294-298.	1.0	82
216	Apolipoprotein A1 Gene Polymorphisms and Risk of Early Coronary Disease. Cardiology, 1998, 90, 231-235.	0.6	40

#	Article	IF	Citations
217	A family with a milder form of adult dominant polycystic kidney disease not linked to the PKD1 (16p) or PKD2 (4q) genes.. Journal of Medical Genetics, 1997, 34, 587-589.	1.5	60
218	Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.. Journal of Clinical Pathology, 1997, 50, 212-217.	1.0	95
219	HLAâ€B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens, 1997, 49, 116-123.	1.0	204
220	Factor V Leiden (R506Q) and risk of venous thromboembolism: a caseâ€control study based on the Spanish population. Clinical Genetics, 1997, 52, 206-210.	1.0	26
221	Fine Physical Mapping of the Human Matrix Metalloproteinase Genes Clustered on Chromosome 11q22.3. Genomics, 1996, 37, 266-269.	1.3	54
222	HLA-B27 structure, function, and disease association. Current Opinion in Rheumatology, 1996, 8, 296-308.	2.0	36
223	Characterization of interleukin-8 receptors in non-human primates. Immunogenetics, 1996, 43, 261-267.	1.2	9
224	Molecular evolution of the N-formyl peptide and C5a receptors in non-human primates. Immunogenetics, 1996, 44, 446-452.	1.2	33
225	Characterization of interleukin-8 receptors in non-human primates. Immunogenetics, 1996, 43, 261-267.	1.2	1
226	Genetic detection of the silent allele (*Q0) in hereditary deficiencies of the human complement C6, C7, and C9 components. American Journal of Medical Genetics Part A, 1995, 55, 408-413.	2.4	5
227	Characterization of B27 haplotypes by oligotyping and genomic sequencing in the Mexican Mestizo population with ankylosing spondylitis: Juvenile and adult onset. Human Immunology, 1995, 43, 174-180.	1.2	36
228	A physical map of two clusters containing the genes for six proinflammatory receptors. Immunogenetics, 1994, 40, 100-3.	1.2	16
229	Molecular analysis of HLA-B27 haplotypes in caucasoids frequencies of B27-Cw in jewish and spanish populations. Human Immunology, 1994, 41, 127-134.	1.2	35
230	A physical map of the human complement component C6, C7, and C9 genes. Immunogenetics, 1993, 38, 341-4.	1.2	25
231	MspI RFLP of the human TCR gamma chain variable gene V9 (TCRGV9). Nucleic Acids Research, 1991, 19, 5806-5806.	6.5	1